In ε4 carriers these mechanisms can lead to hypercholesterolemia and pro-atherogenic circulating lipoprotein-cholesterol distributions such as more cholesterol enriched chylomicron remnants and apoB-containing lipoproteins, as well as higher VLDL-C/HDL-C ratio5,6,32. This evidence concerns the gene APOB and Hypercholesterolemia.